D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 62 Citations 13,142 113 World Ranking 1565 National Ranking 784

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Immune system
  • Gene

His primary areas of investigation include Immunology, Immune system, Antigen, Antibody and Immunity. As a part of the same scientific study, Martin A. Cheever usually deals with the Immunology, concentrating on Cytotoxic T cell and frequently concerns with Leukemia. His Leukemia study contributes to a more complete understanding of Internal medicine.

Martin A. Cheever works mostly in the field of Immune system, limiting it down to concerns involving Adjuvant and, occasionally, Toxoid, Tetanus and Immunocompetence. His Antibody study incorporates themes from Cancer, Breast cancer and Major histocompatibility complex. His research in Immunotherapy intersects with topics in Epitope, In vitro and CTL*.

His most cited work include:

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma (705 citations)
  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma (705 citations)
  • Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia (495 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Immunology, Immune system, Antigen, Leukemia and Cancer research. His Immunology study frequently involves adjacent topics like Cytotoxic T cell. His Immune system research focuses on Spleen and how it relates to Chemoimmunotherapy.

His studies in Leukemia integrate themes in fields like Cyclophosphamide, Surgery and Chemotherapy. His Chemotherapy research incorporates themes from Bone marrow and Pathology. His studies deal with areas such as Gastroenterology and Oncology as well as Internal medicine.

He most often published in these fields:

  • Immunology (50.00%)
  • Immune system (36.81%)
  • Antigen (36.11%)

What were the highlights of his more recent work (between 1995-2020)?

  • Immunology (50.00%)
  • Immune system (36.81%)
  • Antigen (36.11%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Immunology, Immune system, Antigen, Molecular biology and Immunotherapy. His works in Antibody, Immunity and Leukemia are all subjects of inquiry into Immunology. He is involved in the study of Immune system that focuses on Active immunization in particular.

His Antigen study integrates concerns from other disciplines, such as Cancer research, Tumor antigen, Homologous chromosome and Virology. The various areas that Martin A. Cheever examines in his Molecular biology study include Epitope, Cytotoxic T cell, CD8 and Her 2 neu. His Immunotherapy study combines topics from a wide range of disciplines, such as Adoptive cell transfer, Priming, Colorectal cancer and Oncology.

Between 1995 and 2020, his most popular works were:

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma (705 citations)
  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma (705 citations)
  • Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines (411 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Immune system
  • Gene

Immunology, Immune system, Antigen, Immunity and Antibody are his primary areas of study. His Immune system study focuses on Active immunization in particular. His Antigen research focuses on Tumor antigen and how it connects with Cellular immunity.

His Immunity research includes themes of Breast cancer, Mammary gland and Vaccination. His Antibody research is multidisciplinary, relying on both Western blot and Major histocompatibility complex. He combines subjects such as Cytotoxic T cell and Leukemia with his study of Myeloid leukemia.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul T. Nghiem;Paul T. Nghiem;Shailender Bhatia;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar.
The New England Journal of Medicine (2016)

911 Citations

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

Mary L. Disis;Emanuel Calenoff;Graham McLaughlin;Ann E. Murphy.
Cancer Research (1994)

706 Citations

Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia

E D Thomas;R A Clift;A Fefer;F R Appelbaum.
Annals of Internal Medicine (1986)

665 Citations

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

Mary L. Disis;Theodore A. Gooley;Kristine Rinn;Donna Davis.
Journal of Clinical Oncology (2002)

538 Citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

Mary L. Disis;Helga Bernhard;Faith M. Shiota;Susan L. Hand.
Blood (1996)

519 Citations

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

Mary L. Disis;Serenella M. Pupa;Julie R. Gralow;Ruggero Dittadi.
Journal of Clinical Oncology (1997)

482 Citations

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

P D Greenberg;M A Cheever;A Fefer.
Journal of Experimental Medicine (1981)

430 Citations

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.

Philip D. Greenberg;Donald E. Kern;Martin A. Cheever.
Journal of Experimental Medicine (1985)

392 Citations

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

M A Cheever;P D Greenberg;A Fefer;S Gillis.
Journal of Experimental Medicine (1982)

353 Citations

Generation of Immunostimulatory Dendritic Cells from Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood

Helga Bernhard;Mary L. Disis;Shelly Heimfeld;Susan Hand.
Cancer Research (1995)

345 Citations

Best Scientists Citing Martin A. Cheever

Mary L. Disis

Mary L. Disis

Fred Hutchinson Cancer Research Center

Publications: 90

Steven A. Rosenberg

Steven A. Rosenberg

National Institutes of Health

Publications: 64

Rainer Storb

Rainer Storb

Fred Hutchinson Cancer Research Center

Publications: 58

John M. Goldman

John M. Goldman

Imperial College London

Publications: 53

Philip D. Greenberg

Philip D. Greenberg

Fred Hutchinson Cancer Research Center

Publications: 49

Keith L. Knutson

Keith L. Knutson

Mayo Clinic

Publications: 46

Ulf Dittmer

Ulf Dittmer

University of Duisburg-Essen

Publications: 45

Richard E. Champlin

Richard E. Champlin

The University of Texas MD Anderson Cancer Center

Publications: 43

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 43

Keith M. Sullivan

Keith M. Sullivan

Duke University

Publications: 41

Jeffrey Schlom

Jeffrey Schlom

National Institutes of Health

Publications: 41

Frederick R. Appelbaum

Frederick R. Appelbaum

Fred Hutchinson Cancer Research Center

Publications: 39

E. Donnall Thomas

E. Donnall Thomas

University of Washington

Publications: 34

Claudio Anasetti

Claudio Anasetti

Fred Hutchinson Cancer Research Center

Publications: 33

Cornelis J. M. Melief

Cornelis J. M. Melief

Leiden University Medical Center

Publications: 32

Nicholas P. Restifo

Nicholas P. Restifo

National Institutes of Health

Publications: 32

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.